Ligands

Subscribe to Selected New Research on Ligands

6543 relevant articles (206 outcomes, 609 trials/studies) found for this Bio-Agent

Description: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Specialty Uses of Chemicals

Laboratory Chemicals

Ligands: 6543

Experts

1.	Cuzzocrea, Salvatore: 6 articles (05/2007 - 07/2002)
2.	Elstner, Elena: 6 articles (08/2006 - 11/2003)
3.	Thiemermann, Christoph: 6 articles (03/2005 - 07/2002)
4.	Tumiatti, Vincenzo: 5 articles (10/2008 - 10/2007)
5.	Minarini, Anna: 5 articles (10/2008 - 10/2007)
6.	Rosini, Michela: 5 articles (10/2008 - 10/2007)
7.	Melchiorre, Carlo: 5 articles (10/2008 - 10/2007)
8.	Phipps, Richard P: 5 articles (01/2008 - 11/2004)
9.	Harnish, Douglas C: 5 articles (11/2006 - 12/2004)
10.	Koeffler, H Phillip: 5 articles (10/2004 - 06/2003)

Related Diseases

1.	Neoplasms (Cancer) 10/24/2007 - "It is noteworthy that, despite the fact that TCL-SPION does not bear any targeting ligands on its surface, it was highly effective for tumor detection in vivo by dual imaging." 06/15/2001 - "Some altered-peptide ligands (APL) of GP2 have increased binding affinity and generate improved cytotoxic T lymphocyte recognition of GP2-presenting tumor cells, but most do not" 06/01/2006 - "However, in the search for potent HDAC inhibitors with cancer therapeutic potential, a tendency exists to overlook or dismiss weak ligands that could prove effective in cancer prevention" 02/01/2006 - "However, in the search for potent HDAC inhibitors with cancer therapeutic potential there has been a tendency to overlook or dismiss weak ligands that could prove effective in cancer prevention, including agents present in the human diet" 09/01/2002 - "Glycosylation proved to be a powerful tool for the development of high affinity sst ligands with excellent excretion profiles and improved tumor accumulation." Order ALL the reference details at left...
2.	Pain (Aches) 10/01/2008 - "Opioid analgesic combinations administered as tethered bivalent ligands or admixture demonstrate good pain relief with improved side effect profiles" 09/01/1998 - "Moreover, these findings offer the I2-imidazoline ligands as promising therapeutic coadjuvants in the management of chronic pain with opiate drugs." 01/01/2007 - "Nicotinic and muscarinic cholinergic ligands represent a novel class of agents with much promise for the management of problematic pain" 06/01/2002 - "The expression of mGluRs throughout the pain neuraxis and the differing roles of the mGluRs in each of these regions makes it difficult to predict the efficacy of mGluR ligands based on in vitro or local administration studies" 08/30/2006 - "Most of them have been suggested to influence pain transmission, but only a few studies have been performed on the interactions of different endogenous ligands" Order ALL the reference details at left...
3.	Infection 01/01/2008 - "We have outlined ligands that have a potential to provide protection against HSV-2 infection" 05/01/2008 - "Using the Theiler's murine encephalomyelitis virus model, the authors found that NKG2D-positive CD8+ cytotoxic T cells enter the brain, that NKG2D ligands are expressed in the brain during acute infection, and that interruption of NKG2D ligand recognition via treatment with a function-blocking antibody attenuates the efficacy of viral clearance from the central nervous system." 08/01/2007 - "We also determined the efficacy of the CCR5 ligands against HIV-1 infection of HeLa-derived cell lines that express CD4 at the same level but vary 2-fold in CCR5 expression (JC.48 and JC.53 cells)" 01/01/2005 - "CXCR3 and its ligands participate in the host response to Bordetella bronchiseptica infection of the mouse respiratory tract but are not required for clearance of bacteria from the lung." 02/01/2008 - "In summary, this study shows that CVB3 interferes with the expression of NK cell receptor ligands on infected cells and indicates that IFN-gamma production, rather than cytotoxicity, marks the early human NK cell response to CVB3 infection." Order ALL the reference details at left...
4.	Inflammation 12/01/1999 - "We propose that these results may be important in terms of lymphocyte circulation; while T cells migrate through the vascular endothelium, they are primed for an amplified response; as inflammation develops, a local accumulation of soluble integrin ligands may help to turn it off." 01/02/2003 - "PBR expression modulation together with the protective effects of its ligands further reinforce the role that PBR may play in the regulation of inflammation processes" 02/01/2000 - "In stark contrast to its role in eliciting pro-inflammatory responses following binding of microbial ligands, macrophage CD14 mediates clearance of apoptotic cells without inciting inflammation" 03/01/2008 - "We hope that our results stimulate other studies designed to evaluate the effects of NOD ligands in animal models of inflammation." 01/01/2008 - "Additionally, previous studies clearly demonstrated the involvement of the LTbetaR interaction with its ligands in promoting intestinal inflammation" Order ALL the reference details at left...
5.	Multiple Sclerosis 09/01/2007 - "This work reports molecular dynamics studies at the receptor level of the immunodominant myelin basic protein (MBP) epitope 87-99 implicated in multiple sclerosis, and its antagonists altered peptide ligands (APLs), namely [Arg91, Ala96] MBP87-99 and [Ala91,96] MBP87-99" 09/01/2007 - "Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response." 01/01/2006 - "This has further implications for neuroinflammatory diseases such as multiple sclerosis, where both cells bearing CCR1/CCR5 plus their ligands, as well as HHV-6A, have been linked" 01/01/2004 - "Phage display technology was used to identify peptide ligands with unique specificity for a monoclonal model antibody, MK16, that recognises the human multiple sclerosis associated MHC class II molecule DR2 in complex with a myelin basic protein (MBP)-derived peptide corresponding to residue 85-99" 11/01/2005 - "Synthetic glycolipid ligands as novel therapeutics for multiple sclerosis]" Order ALL the reference details at left...

Related Drugs and Biologics

1.	PPAR gamma
2.	Peroxisome Proliferator-Activated Receptors (PPAR)
3.	Thiazolidinediones
4.	PPAR alpha
5.	sigma Receptors (sigma Receptor)
6.	GABA-A Receptors (GABA(A) Receptor)
7.	Proteins (Proteins, Gene)
8.	Antigens
9.	Hormones
10.	Toll-Like Receptors (Toll-Like Receptor)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Chemoprevention
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18530 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>